Kornimate/medical-research-clean huggingface dataset:
using eeg to study coma in the neurocritical care unit

Conditions: Coma

Summary: despite its clinical significance, the pathophysiology of coma is still under investigation and the physiology of emergence from coma remains a mystery. furthermore, predictors of emergence from coma, despite their obvious clinical value, remain un-established. because of its low arousal state and hypothesized parallel neurophysiological mechanisms, sleep has been studied as both an animal and human model of coma, and awakening from sleep has likewise been studied as a surrogate of coma emergence. in this study, we will determine whether certain electrographic patterns, known as spectral shifts, which have correlates in normal sleep, are predictive of eventual awakening from coma and the time course of this emergence. to detect spectral shifts in comatose patients, eeg monitoring must be performed for several days. quick, simple, and reliable eeg recording in the icu will be enhanced by a small device that can be easily and properly positioned on the head by hospital personnel and which lacks cumbersome cables or receivers. traditional eeg monitoring requires placement of up to 25 wires, which can impede efficient intensive patient care. our hypothesis is that we can detect a difference in spectral shifts in comatose patients who will eventually emerge from coma as compared to comatose patients who do not wake up and that a wireless eeg patch-type device can effectively make this distinction.


Eligibility criteria:
inclusion criteria: all patients with brain injuries admitted to the neurocritical care unit will be screened for enrollment. the estimated enrollment will be for 100 patients. 90 patients will be comatose with glascow coma scale \< 9. the other 10 patients will be control, non-comatose patients for quality control of the device. consent for inclusion will be obtained from the patient or next of kin for all enrolled patients. exclusion criteria: none
improving rates of repeat colorectal cancer screening

Conditions: Colorectal Neoplasms

Summary: the united states preventive services task force (uspstf) recommends colorectal cancer (crc) screening using fecal occult blood testing (fobt), sigmoidoscopy, or colonoscopy in adults, beginning at age 50 and continuing until age 75. however, rates of crc screening remain inadequate. in 2006, only 60.8% of adults 50 or older reported recent crc screening. screening rates are even lower among black and hispanic populations and in areas with higher poverty rates. annual or biennial fobt testing over many years is essential for fobt to be effective. few studies have examined the rate of repeat fobt testing; to the investigators knowledge, none have been conducted in populations with high prevalence of barriers to screening (e.g., low literacy, varied cultural norms, and transportation difficulties). the assumption that fobt is an effective crc screening strategy presumes it will be done at least biennially, and cost-effectiveness studies of crc screening strategies have found that the results are sensitive to the rate of adherence. the investigators study will provide critical information for providers and policymakers as they consider optimal strategies to increase crc screening among vulnerable populations. overall study goal: improve colorectal cancer screening by increasing rates of repeat fecal occult blood testing (fobt). aim 1: test if a multifaceted intervention increases repeat fobt testing adherence over a 30-month period hypothesis 1: compared to usual care, the intervention will increase the proportion of patients who complete a repeat annual fobt within 6 months of their due date. hypothesis 2: compared to usual care, the intervention will increase the proportion of patients who complete 2 additional fobts over the 30-month intervention period. aim 2: explore perceived barriers to screening among patients who received the intervention but did not complete repeat fobt testing within 18 months aim 3: assess the costs of the intervention and the costs per additional repeat screening compared to patients who received usual care.


Eligibility criteria:
inclusion criteria: * fecal occult blood test (fobt) completed in the past year * age 51-75 * preferred language english or spanish exclusion criteria: * any of the following: (1) colonoscopy within 10 years (2) flexible sigmoidoscopy within 5 years or (3) a clinician order or referral for fobt prior to the due date * documentation of medical conditions suggesting colorectal cancer (crc) screening through fobt may be inappropriate including: chronic diarrhea, inflammatory bowel disease, iron deficiency, previous colonic polyp, use of medications in the previous 1 month that elevate the risk of a false-positive fobt

Keywords: colorectal cancer screening fecal occult blood testing
depression care management for depressed elders in china primary care

Conditions: Depression

Summary: using a randomized controlled design, the investigators will examine whether the dcm is an effective treatment for patients with late life depression in urban china. our specific aims are: (1) to determine whether the dcm intervention results in improved outcomes compared with cau at both the provider (e.g., greater adherence to quality indicators) and patient levels (e.g., greater reduction in depressive symptoms); and (2) to compare dcm with cau with regard to a range of outcomes in other pertinent domains, both at the provider (e.g., improvements in knowledge/attitudes) and patient (e.g., functioning, satisfaction) levels. the study will take place in 16 primary care clinics (pccs) randomly assigned to deliver either dcm or cau (8 clinics each) to 320 patients (aged≥60 years) with major depression (20/clinic; n=160 in each treatment condition). in the dcm arm, pcps will prescribe 16 weeks of antidepressant medication according to the tg protocol. cms monitor the progress of treatment and side effects, educate patients/family, and facilitate communication between providers; psychiatrists will provide weekly group psychiatric consultation and cm supervision. patients in both dcm and cau arms will be assessed by clinical research coordinators at baseline, 4, 8, 12, 18, and 24 months. hdrs, mmse, cas, sf-12, treatment stigma and the client satisfaction questionnaire will be used to assess patients' outcomes; and clinic practices, attitudes/knowledge, and satisfaction will be providers' outcomes.

* at the patient level: the investigator will gather information about age, gender, education, marital status, living conditions and satisfaction with their economic status, as well as systematic information on suicidal ideation,, psychopathology, medical health, cognitive function, quality of life and stigma and satisfaction for the treatment. * at the provider level: the objective of research measures at the provider level is to gather social-demographic data such as age, gender, education, marital status, clinical experience among physicians in the participating pccs as well as systematic information on their attitudes/knowledge regarding depression and clinical practices with the treatment guidelines.

Eligibility criteria:
inclusion criteria: * age ≥ 60 years old * community-dwelling residences * capable of independent communication * mini-mental state examination (mmse) score ≥ 18 exclusion criteria: * incapable of giving written informed consent to this study * acute high suicide risk at baseline assessment * psychosis

Keywords: elderly care management primary care
epicardial fat, visceral fat and coronary atherosclerosis

Conditions: Epicardial Fat; Visceral Fat; Atherosclerosis

Summary: background: visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. the independent role of epicardial fat deposition in cardiovascular risk remains unclear.

background: visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. the independent role of epicardial fat deposition in cardiovascular risk remains unclear. aim: evaluate the link between epicardial fat, visceral fat, liver fat accumulation and cardiovascular diseases and carotis atherosclerosis in patients with the major cardiovascular risk factors and with or without metabolic syndrome.

Eligibility criteria:
inclusion criteria: * patients referred to cardiac ct will be the source of recruitment. * patients with excess of visceral fat, * 30 patients with liver fat accumulation * 30 sex-age-matched individual (controls) will be enrolled. all patients will undergo a complete family history, personal clinical history, physical examination and blood sampling for biochemical analysis. * informed consent will be obtained from each individual. exclusion criteria: * subjects with severe morbid obesity (body mass index \[bmi\] \> 40), * recent history of acute illness, * clinical history of ischemic heart disease and cerebrovascular disease, * typical chest pain, * previous coronary artery disease, * conventional coronary angiography, percutaneous interventions, coronary by pass grafting, renal failure, cancer patients, * subjects who take drugs that induces hepatic steatosis ( corticosteroids, estrogens, methotrexate, amiodarone and others)

Keywords: epicardial fat visceral fat atherosclerosis coronary computed tomography angiography carotid doppler ultrasound
evaluation of neuroendocrine differentiation as a potential mechanism of tumor recurrence following radiotherapy

Conditions: Prostate Cancer

Summary: this is a pilot study to test a hypothesis that a greater increase in serum chromogranin a (cga) after a definitive radiotherapy (rt) with or without androgen deprivation therapy (adt) is associated with a higher risk of prostate cancer recurrence after rt. serum cga level is measured before the start of rt and/or the start of neoadjuvant adt for patients undergoing a definitive rt with or without adt. cga is also measured at various pre-defined post-rt time points. the study will analyze the followings: 1. change in cga level at various pre-defined post-rt time points from the baseline, 2. correlation between the extent of post-therapy cga change and gleason score of malignancy, 3. correlation between the extent of post-therapy cga change and treatment outcome.

neuroendocrine differentiation (ned) in prostate cancer is a well-recognized phenotypic change by which prostate cancer cells transdifferentiate into neuroendocrine-like (ne-like) cells. accumulated evidences have suggested that the prevalence of ne-like cells is associated with disease progression and poor prognosis. ned can be induced by a therapeutic agent. such therapeutic agents include rt and adt. rt-induced ned represents a novel pathway by which prostate cancer cells survive radiotherapy and contribute to treatment failure and tumor recurrence. chromogranin a is the serum biomarker for ned and correlates well with cga-positive staining in biopsy specimens. it has been reported that elevated serum cga is associated with poor therapeutic response, androgen-independent growth, and biochemical recurrence. the study tests whether the extent of serum cga increase by rt +/- adt, which reflects radiation-induced ned, is correlated with the risk of prostate cancer recurrence following rt and a gleason score of prostate carcinoma.

Eligibility criteria:
inclusion criteria: * clinically localized prostate carcinoma, t1-t4 n0m0, any gleason score, any prostate-specific antigen (psa), or biochemical relapse with clinically suspicious (based on mri or clinical examination) or biopsy-proven local recurrence in the prostatic fossa after a radical prostatectomy * ≥18 years old * histologic diagnosis of prostate adenocarcinoma * signed informed consent exclusion criteria: * biochemical relapse alone without clinically suspicious (i.e. no suspicious lesion on mri of the prostatic bed) or biopsy-proven local recurrence in the prostatic fossa * regional pelvic node metastasis (n1) * distant metastasis (m1) * concurrent or previous cytotoxic medications * medical or psychological conditions that in the opinion of the investigator would not allow follow-up

Keywords: radiotherapy chromogranin a neuroendocrine differentiation
comparison of single intra-articular injection of hyruan-one with hylan g-f 20 in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: we compare the efficacy of intra-articular injection of hyruan-one with hylan g-f 20 and placebo (nss) controlled in a double-blind rct.


Eligibility criteria:
inclusion criteria: * symptomatic primary knee osteoarthritis with failed conservative treatment at least 3 months * kellgren-lawrence grade i-iii * gave informed consent * can do questionnaires exclusion criteria: * severe deformity (varus or values from mechanical axis more than 5 degrees * allergy to hyaluronic acid * pain on hip or ankle * post-traumatic or post surgery of lower extremity * post infection of knee * previous hyaluronic acid injection within 6 months * pregnancy or lactation * underlying rheumatoid arthritis, stroke, malignancy, venous occlusion

Keywords: hyruan-one hylan g-f 20 hyaluronic acid knee osteoarthritis pain level
efficacy of iron bisglycinate in treatment of iron deficiency anemia in pregnant women

Conditions: Iron Deficiency Anemia of Pregnancy

Summary: anemia in pregnancy is defined by the world health organization as hemoglobin levels of ≤ 11 g/dl. globally, a prevalence rate of 38% was estimated by the world health organization for pregnant women.treatment of iron deficiency anemia during pregnancy remains a main public health issue. oral iron salts have been recommended for treatment of iron deficiency anemia e.g. ferrous fumarate. increasing the dose of ferrous fumarate will subsequently increase the bioavailability of iron preparation, however it also increases the frequency of gastrointestinal tract side effects e.g. nausea, constipation, diarrhea, flatulence, and black stained stools. besides, the increased bioavailable ferrous fumarate may decrease by many foods and / or chelating drugs in the gastrointestinal tract which interfere with its absorption leading to variability in the hemoglobin correction during the treatment. ferrous bisglycinate is an iron amino acid chelate. it is formed by reaction of ferrous iron with two molecules of the amino acid glycine by a covalent bound in a process called chelation. ferrous bisglycinate is claimed to have better patient compliance because of fewer gastrointestinal tract side effects. it is also claimed that ferrous bisglycinate improves iron absorption, storage and increase hemoglobin level better than the conventionally used iron salts.


Eligibility criteria:
inclusion criteria: * pregnant women aged 20 to 40 years, * 14-27 gestational weeks calculated from the first day of their last menstrual period and confirmed by ultrasound * singleton fetus * hemoglobin level from 7-9.9 g/dl. exclusion criteria: * all women with high risk pregnancy e.g. hypertension, diabetes * multiple pregnancy * women with severe anemia (hb \>7 g/dl) * anemia due to other causes than iron deficiency as chronic blood loss, hemolytic anemia or thalassemia. * women with hepatic, renal or cardiovascular abnormality; women with peptic ulcer, esophagitis, gastritis or hiatus hernia * family history of thalassemia, sickle cell anemia, or malabsorption syndrome * hypersensitivity to iron preparations or current use of iron supplementation.
spanish wilson disease registry

Conditions: Wilson Disease

Summary: the main objective and purpose of the registry is to know the current status of wilson disease in spain. as secondary objectives, the prevalence and incidence of the disease will be analysed. likewise, the analysis aims to define future areas of interest in its pathogenesis, diagnosis, natural history, follow-up, prognosis and treatment. improving knowledge at a national level can help to design screening strategies and improve diagnostic circuits.

retrospective and prospective study.

Eligibility criteria:
inclusion criteria: * patients with a confirmed wilson disease diagnosis exclusion criteria: * refusal to sign the informed consent for the study

Keywords: genetic disease registry copper wilson disease
comparative effects of dry needling and cross friction massage on patients with plantar fascitis, rct

Conditions: Plantar Fascitis

Summary: effectiveness comparative effects of dry needling and cross friction massage on patients with plantar fascitis


Eligibility criteria:
inclusion criteria: * patients with plantar fascitis exclusion criteria: * other health issues
impact of treatment with venarus® on the level of monocyte chemoattractant protein 1 in varicose veins blood

Conditions: Varicose Veins

Summary: this study is designed to find if the venoactive drug contained diosmin and hesperidin is able to work against chronic vein-specific inflammation by changing the level of monocyte chemoattractant protein 1. this chemokine is involved in the vein wall remodeling in patients with lower limb varicose veins.

the study is a post-registration open-label observational prospective single-center study with minimal intervention. individuals aged 18-50 with varicose veins and ceap c2-c4, ep, as, pr will be invited to participate in the study. those who agree, will be examined both clinically and by duplex ultrasound. medical history of participants will be taken, demographic data will be collected. blood will be drawn from the varicose vein of the affected limb. discomfort in the affected limb will be evaluated by a visual-analog scale. duplex ultrasound will be used in every resident to reveal pathological venous reflux in deep and superficial veins.

Eligibility criteria:
inclusion criteria: * • both female and male * age from 18 to 50 years old * verified diagnosis of chronic venous insufficiency ceap c2-c4 * signed infromed consent * absence of any other treatment 2 weeks before the start of the study and throughout the duration of the study exclusion criteria: * • age less than 18 and more than 50 years * previously performed invasive interventions for varicose veins on any of the lower extremities * no visible varicose veins * thrombophlebitis and deep vein thrombosis of the lower extremities in the past * taking prohibited pre-trial therapy * contraindications to taking venarus® * not signed informed consent
a phase i, randomized, placebo-controlled, double blind, repeat dose escalation study to evaluate the safety, tolerability, pharmacokinetics, gastrointestinal transit time and pharmacodynamic biomarkers of gsk3179106 in normal subjects

Conditions: Irritable Bowel Syndrome

Summary: the current study is designed to assess the safety, tolerability, pharmacokinetics (pk), gastrointestinal (gi) transit time and pharmacodynamic (pd) biomarkers of repeat oral doses of gsk3179106 administered for 14 days in normal healthy subjects. it is a randomized, double-blind, placebo-controlled, ascending cohort study. a total of 48 subjects will be randomized (8 subjects/cohort) with 3:1 allocation to gsk3179106 or matching placebo.


Eligibility criteria:
inclusion criteria: * between 18 and 55 years of age inclusive, at the time of signing the informed consent. * healthy as determined by the investigator based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. history of regular bowel habits * male or female of non-childbearing potential. * capable of giving signed informed consent which includes compliance with the requirements and restrictions exclusion criteria: * alt and bilirubin \>1.5xupper limit of normal (uln) (isolated bilirubin \>1. uln is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * estimated glomerular filtration rate \<60 milliliter per minute per 1.73 square meter (ml/min/1.73m\^2) * current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of gilbert's syndrome or asymptomatic gallstones) * history of gastroesophageal reflux disease (gerd), dyspepsia, gi bleeding, gi surgery that could affect motility

Keywords: rearranged during transfection growth factor receptor tyrosine kinase inhibitor
safety of diclofenac sodium gel in knee osteoarthritis

Conditions: Osteoarthritis

Summary: this study will test the efficacy and safety of topical voltaren in the treatment of knee osteoarthritis.


Eligibility criteria:
key inclusion criteria • osteoarthritis of the knee key exclusion criteria * other rheumatic disease, such as rheumatoid arthritis * active gastrointestinal ulcer during the last year * known allergy to analgesic drugs

Keywords: knee osteoarthritis, topical nsaid, diclofenac sodium
the livmor data collection study for the development and validation of l-1000af system

Conditions: Atrial Fibrillation

Summary: the livmor data collection study is a multicenter, ide exempt study to generate a library of device-specific signals collected noninvasively. the study was not designed to evaluate specific hypothesis or endpoint, rather it was intended for data collection purposes to generate a library of raw clinical data that were retrospectively used for the development and subsequently the validation of the l-1000af system. the l-1000af system is a wrist worn system intended to provide continuous remote monitoring of atrial fibrillation (af) episodes. the system is intended for use under the care of a physician and is not intended for the diagnosis of af.

livmor is developing a series of wearable medical device systems intended to promote general wellness and help subjects and physicians manage various diseases that can benefit from increased visibility of physical activity, sleep, weight, blood pressure, stress/recovery levels and cardiac rhythms. data from human subjects is necessary to develop and validate livmor devices. livmor completed a multicenter, ide exempt study to generate a library of device-specific signals collected non-invasively using components of the livmor system and simultaneously acquired with ecg holter data using a commercially available holter monitor. data from the analysis of the holter monitor was adjudicated by physicians skilled in the analysis and interpretation of ecgs compared to the analysis from the livmor af detection algorithm to establish the sensitivity and specificity of the algorithm for detection of af in comparison to ground truth. the study was not designed to evaluate specific hypotheses or endpoint, rather it was intended for data collection purposes to generate a library of raw clinical data that were retrospectively used for the development and subsequently the validation of the l-1000af system.

Eligibility criteria:
inclusion criteria: * willing, able and sufficiently motivated to attend all study visits and participate in all study activities; and * physically and mentally capable of providing informed consent and are at least 18 years of age or of legal age to provide consent as required by local and national requirements. exclusion criteria: * has any unstable or significant medical condition that is likely to interfere with study procedures or subjects medical care; * has any implantable electronic medical device; * has significant hearing, visual or cognitive impairment as determined by the investigator; and * participating in any other clinical study without written consent from the sponsor